FDA Approves BUPRENORPHINE AND NALOXONE — Camber Pharmaceuticals, Inc.

Camber Pharmaceuticals, Inc. received FDA approval for its Abbreviated New Drug Application (ANDA219727) for the sublingual formulation of buprenorphine and naloxone, now available for the treatment of opioid use disorder. This expansion of treatment options is positioned to increase patient access and address supply chain constraints in the market.